9 December 2022
EMA/CVMP/903852/2022
Committee for Veterinary Medicinal Products

Summary of opinion[1] (post-authorisation)

Credelio Plus

International non-proprietary name (INN): lotilaner / milbemycin oxime

On 8 December 2022, the Committee for Veterinary Medicinal Products (CVMP) adopted a positive opinion[2], recommending the granting of a variation to the terms of the marketing authorisation for the veterinary medicinal product Credelio Plus. The marketing authorisation holder for this veterinary medicinal product is Elanco GmbH.

Credelio Plus is currently authorised as chewable tablets for use in dogs. The variation concerns the addition of a new therapeutic indication for the treatment of demodicosis (caused by *Demodex canis*).

Detailed conditions for the use of this product are described in the summary of product characteristics (SPC), for which an updated version reflecting the changes will be published in the revised European public assessment report (EPAR) and will be available in all official European Union languages after the variation to the marketing authorisation has been granted by the European Commission.

[1] Summaries of opinion are published without prejudice to the Commission Decision.
[2] Applicants may appeal any CVMP opinion, provided they notify the European Medicines Agency in writing of their intention to appeal within 15 days of receipt of the opinion.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union